Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Abstract Background In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive...

Full description

Bibliographic Details
Main Authors: Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun (Nicole) Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim, Scot Ebbinghaus
Format: Article
Language:English
Published: BMJ Publishing Group 2019-02-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
RECIST
Early efficacy metrics
Early tumor size changes
Cut-off values
Immunotherapy trials
Online Access:http://link.springer.com/article/10.1186/s40425-019-0513-4

Internet

http://link.springer.com/article/10.1186/s40425-019-0513-4

Similar Items